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The current dopamine (DA) hypothesis of schizophrenia postu-
lates striatal hyperdopaminergia and cortical hypodopaminergia.
Although partial agonists at DA D2 receptors (D2Rs), like aripipra-
zole, were developed to simultaneously target both phenomena,
they do not effectively improve cortical dysfunction. In this study,
we investigate the potential for newly developed β-arrestin2
(βarr2)-biased D2R partial agonists to simultaneously target hyper-
and hypodopaminergia. Using neuron-specific βarr2-KO mice, we
show that the antipsychotic-like effects of a βarr2-biased D2R ligand
are driven through both striatal antagonism and cortical agonism of
D2R-βarr2 signaling. Furthermore, βarr2-biased D2R agonism en-
hances firing of cortical fast-spiking interneurons. This enhanced
cortical agonism of the biased ligand can be attributed to a lack of
G-protein signaling and elevated expression of βarr2 and G protein-
coupled receptor (GPCR) kinase 2 in the cortex versus the striatum.
Therefore, we propose that βarr2-biased D2R ligands that exert
region-selective actions could provide a path to develop more effec-
tive antipsychotic therapies.
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Gprotein-coupled receptors (GPCRs) represent the largestfamily of receptors in the human genome and are one of the
most common targets of pharmaceutical drugs (1, 2). Upon ligand
binding, GPCRs activate downstream G protein-dependent sig-
naling pathways followed by phosphorylation of the receptor by G
protein-coupled receptor kinases (GRKs) (3). Phosphorylation
enhances association of the GPCR with β-arrestins (βarrs), and
this combined process mediates desensitization of G-protein sig-
naling (4) and internalization of GPCRs (5–7). Two isoforms of
βarrs, βarr1 and βarr2, are widely coexpressed in most tissues in
mammals and are 80% identical, but they can have either over-
lapping or distinct functions (8, 9). It is now firmly established that
GPCRs activate downstream signaling pathways through not only
canonical G-protein pathways but also, the ability of βarrs to
scaffold distinct intracellular signaling complexes (10–12). Eluci-
dation of these distinct G-protein and βarr signaling pathways has
provided support for the concept of functional selectivity or biased
signaling, wherein each signaling pathway has the ability to me-
diate distinct physiological responses (13). There are now several
physiologically relevant examples of selective engagement of sig-
naling pathways or selective GPCR ligands that target these dif-
ferent signaling pathways (13–15). Therefore, leveraging the
concept of GPCR functional selectivity holds promise for the de-
velopment of more selective therapeutic approaches.
Dopamine (DA) is a catecholamine neurotransmitter that has
been implicated in movement, reward, and cognition (16–19) as
well as CNS disorders, such as schizophrenia, attention deficit hy-
peractivity disorder, Parkinson’s disease, and obsessive–compulsive
disorder (20–23). DA mediates its effects via GPCRs belonging
to two major subclasses of receptors: the D1 class [D1 receptor
(D1R) and D5 receptor] and the D2 class [D2 receptor (D2R),
D3 receptor, and D4 receptor] (24), a classification based on their
ability to activate the stimulatory G protein Gαs/olf or inhibitory G
protein Gαi/o signaling pathway, respectively. In the brain, D2Rs
activate canonical Gαi/o-mediated signaling to inhibit adenylyl cy-
clase, cyclic adenosine monophosphate (cAMP) production, and
the protein kinase A/dopamine and cAMP regulated phospho-
proteinMr 32 KDa (PKA/DARPP32) pathway to mediate many of
the behavioral effects of DA (23, 25, 26). However, based on the
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initial observation that the DA-dependent locomotor response to
amphetamine (AMPH) was markedly attenuated in mice globally
lacking βarr2 but not βarr1 (9), we provided biochemical and
genetic evidence for a βarr2-dependent signaling pathway down-
stream of D2Rs that is separate from Gαi/o signaling (27). We have
shown that this D2R-βarr2 signaling pathway inhibits protein ki-
nase B (PKB or AKT) activity, activates glycogen synthase kinase 3
beta (GSK3β), and can mediate specific DA-dependent be-
haviors (28–30).
D2Rs are the major target for most antipsychotic drugs (APDs),
which are the first-line treatment for schizophrenia (31, 32). APDs
do not treat all symptoms of schizophrenia effectively and have
several side effects that are thought to be associated with Gαi/o
signaling (26, 30). APDs that selectively target the D2R-βarr2
pathway could be therapeutically beneficial without producing
extrapyramidal side effects. To further investigate the potential
role of functional selectivity of the D2R-βarr2 pathway in APD
action, we have recently generated βarr2-biased D2R ligands
based on the scaffold of the partial agonist APD aripiprazole
(ARI) (33, 34). These biased ligands show antipsychotic-like pro-
file in pharmacological [phencyclidine (PCP) and AMPH] and
genetic (NMDA receptor NR1 subunit knockdown) mouse models
of schizophrenia-like phenotypes that depend on their D2R-βarr2
selectivity, because their activity is lost in global βarr2-KO mice
(33, 35). Although classical APDs, like haloperidol, and newer
APDs, like ARI, reverse the postulated striatal hyperdopaminergic
tone associated with schizophrenia, none of these drugs effectively
correct cortical dysfunction (36–38). It is currently not known
whether targeting D2R-βarr2 signaling might represent an al-
ternative strategy to identify more broadly effective APDs.
In this study, we used βarr2-biased D2R ligands and behavioral
and electrophysiological approaches in mice lacking βarr2 in var-
ious D2R-expressing neuronal populations to investigate whether
region-specific D2R-βarr2 signaling contributes to unique anti-
psychotic-like effects in vivo.
Results
Determinants of in Vitro D2R-βarr2 Functional Selectivity. Clinically
effective APDs are either antagonists or partial agonists at both
D2R-G protein and D2R-βarr2 signaling pathways (39, 40). We
have previously shown that the βarr2-biased D2R ligands
UNC9994A (94A) and UNC9975A (75A), which are based on the
scaffold of ARI, are weak selective partial agonists at D2R-βarr2
interactions and have little or no agonist activity at D2R-G protein
signaling (33). However, we show in Fig. 1 that the agonist versus
antagonist profiles of these ligands at D2R-βarr2 interactions in
HEK293 cells can be modulated by the complement of GRK2 and
βarr2. In a bioluminescence resonance energy transfer (BRET)-
based assay (Fig. 1 A, C, and E), compared with DA ARI, 94A and
75A are very weak partial agonists at mediating D2R-βarr2 inter-
actions, but increasing GRK2 levels in these cells markedly en-
hanced the partial agonist activity of only ARI and 94A. Consistent
with pharmacological principles, when tested as antagonists (Fig. 1
B, D, and F), all three ligands fully antagonized DA-mediated
D2R-βarr2 interactions, and high GRK2 levels reduced the an-
tagonist efficacy of only ARI and 94A. The profile of 75A was not
significantly changed by GRK2, suggesting that it may have slightly
different properties than ARI or 94A. However, in a D2R–G
protein (GloSensor) assay, ARI and 75A but not 94A behaved as
antagonists (Fig. S1 and Table S1), suggesting that only 94A is a
completely selective D2R-βarr2 ligand. These results are consistent
with the established concept that βarr-dependent GPCR functions
are not only dependent on agonist activation but also, enhanced by
phosphorylation of the receptor by GRKs (11, 41) and that the
expression levels of βarr2 and GRK2 can regulate GPCR signaling
and the pharmacological profile of ligands (42–44).
Previous studies have suggested that the levels of GRKs and
βarrs can vary significantly between tissues and brain areas (45, 46).
Protein levels of βarr2 and GRK2 but not βarr1 are higher in the
prefrontal cortex (PFC) compared with the striatum (STR) in mice
(Fig. 2 A–D) and humans (Fig. S2 A and B) (Ps < 0.05). Because
ARI and 94A gain D2R-βarr2 partial agonism on GRK2 over-
expression, we hypothesized that these compounds might behave
as agonists in the PFC (high βarr2/GRK2). Previous studies have
shown that local injection of the D2R agonist quinpirole can exert
antipsychotic-like effects, because it inhibits locomotion induced by
the NMDA receptor antagonist PCP (47). PCP-induced locomo-
tion is a pharmacologically induced behavior commonly inhibited
by APDs, and the behavioral effects of PCP are thought to be
mediated by cortical disinhibition (48). To assess whether PFC
D2R-βarr2 agonism can elicit antipsychotic-like effects, we mea-
sured the effects of injecting quinpirole, ARI, and 94A locally into
the PFC of WT mice on PCP-induced locomotion. Consistent with
previous findings, local bilateral PFC injection of the unbiased full-
agonist quinpirole significantly inhibited PCP-induced locomotion
(Fig. 2E, QUIN) (P < 0.01); 94A mimicked this D2R agonist ac-
tion (Fig. 2E, 94A) (P < 0.05) and inhibited PCP-induced loco-
motion, whereas the effect of ARI was weaker and did not
reach significance. Coadministration of a pharmacological GRK2
inhibitor [compound 101 (cpd101)] prevented the 94A-mediated
inhibition of PCP-induced locomotion (Fig. 2F, cpd101/94A).
These results are consistent with our in vitro data, showing that, in a
D2R-βarr2 interaction BRET assay, the ability of GRK2 to enhance
the agonist effects of both DA and UNC9994A is lost in presence
of the GRK2 inhibitor (cpd101) (Fig. S2C). These observations
Fig. 1. Effects of GRK2 overexpression on the agonist or antagonist profile of
D2R ligands in HEK293 cells. (A) ARI, (C) UNC9975A (75A), and (E) UNC9994A
(94A) were tested in agonist mode in a D2R-βarr2 interaction BRET assay with
endogenous GRK2 (solid lines) or GRK2 overexpression (dashed lines) com-
pared with DA (black lines) in HEK293 cells. D2R-βarr2 BRET antagonist assays
for (B) ARI, (D) UNC99975A (75A), and (F) UNC9994A (94A) with endogenous
GRK2 (solid lines) or overexpressed GRK2 (dashed lines) levels in HEK293 cells.
Data are presented as inhibition of the total DA response (mean ± SEM).














show that D2R-βarr2 agonism in the PFC is sufficient to inhibit
PCP-induced locomotion, and this effect is dependent on βarr
and GRK2.
Distinct Striatal Vs. Cortical Role of D2R on PCP-Mediated Behavioral
Response. Although D2R PFC agonism inhibits PCP-induced lo-
comotion, striatal D2R antagonism is thought to be the primary
mechanism of action of most APDs (49, 50). To broadly explore
this paradoxical role of D2R function behaviorally, we selectively
deleted D2Rs in either the PFC by injecting an mCherry-Cre
adeno-associated virus (AAV) in the previously described D2R
floxed (D2f/f) mice (51) or the STR by crossing D2f/f mice with
adenosine 2A receptor Cre (A2aCre) mice (Fig. S3), and we tested
the effect on PCP-induced locomotion. We observed that, com-
pared with controls, deletion of D2Rs in the PFC resulted in an
enhanced response to acute PCP injection (Fig. 3A) (Ps < 0.01),
consistent with D2R agonism playing an inhibitory role on the PCP
response (47). However, deletion of D2Rs in the STR attenuated
the PCP response (Fig. 3B) compared with controls (Ps < 0.01),
consistent with striatal D2R antagonism inhibiting PCP-mediated
responses (49, 50). These pharmacological and behavioral data
suggest distinct roles for D2R signaling in the PFC versus the STR
in mediating antipsychotic-like effects.
Generation and Characterization of βarr2 Floxed Mice. To further
evaluate the potential opposite role of D2R-βarr2 signaling in the
PFC and STR in antipsychotic-like effects, we generated a βarr2
floxed (βarr2f/f) mouse line for region- and cell-specific Cre-
dependent deletion of βarr2 (details are in Materials and Methods
and SI Materials and Methods; Fig. S4 A and B); βarr2f/f mice were
indistinguishable from C57BL/6J mice in standard behavioral tests
(Fig. S4 C–E). Deleting βarr2 in all neurons (βarr2f/f CMV-Cre)
recapitulated the decrease in the AMPH locomotor response
originally observed in whole-body βarr2KO mice (27) (Fig. S4
F–H). We have previously shown that the AMPH locomotor response
is mediated at least in part by D2Rs in a βarr2-dependent manner (27,
29), but D2Rs are expressed in multiple regions of the brain, such as
midbrain, STR, and PFC (24, 52–57). To confirm which D2R+
population of neurons is responsible for the AMPH response, we
deleted βarr2 in several distinct neuronal populations; βarr2f/f mice
were crossed with either D2Cre (all D2R+ neurons) or A2aCre
(postsynaptic D2R+ striatal neurons) mice as well as the D1Cre
(D1R+ neurons) or ChaTCre (cholinergic interneurons) mice as
controls. Using immunohistochemistry (IHC) and real-time quantita-
tive PCR techniques, we confirmed selective deletion of βarr2 in ap-
propriate neuronal populations of all Cre lines crossed with the βarr2f/f
mice (Fig. S5). As shown in Fig. 4, βarr2 in striatal D2R+ neurons
seems to play the most prominent role in the AMPH response, be-
cause the locomotor response is reduced only in D2R+ or A2aR+
neurons lacking βarr2 (Fig. 4 E–H) but not affected by deletion of
βarr2 in either D1R+ neurons alone or cholinergic interneurons (Fig.
4 C, D, and I). These data suggest that deleting βarr2 in D2R striatal
neurons is sufficient to mimic antipsychotic-like activity. Importantly,
the mice in which βarr2 is inactivated in select D2R+ neuronal pop-
ulations provide unprecedented models to critically examine the in
vivo antipsychotic-like function of our D2R-βarr2–biased compounds.
Region-Specific Responses of Antipsychotics and βarr2-Biased D2R
Ligands. AMPH- and PCP-induced hyperlocomotion are the two
commonly used pharmacological models to test APD efficacy.
Most APDs are D2R partial agonists or antagonists with varying
potencies and efficacies (31, 32, 40, 58) and inhibit either the
AMPH- or PCP-induced locomotor response in mice (59). The
AMPH-induced locomotor response is dependent on striatal DA
release, whereas the behavioral effects of PCP are thought to be
mediated by cortical disinhibition and activation of the cortico-
striatal pathway (48, 50). We tested the ability of representative
first, second, and third generation APDs, such as haloperidol,
clozapine, and ARI, respectively, along with the βarr2-biased D2R
ligands 94A and 75A in both of these pharmacological models.
Optimal doses for APDs and the D2R-βarr2–biased ligands were
based on previous studies (30, 33, 35).
For the AMPH-induced locomotor response, AMPH was in-
jected at a dose (3 mg/kg) at which there were no significant
Fig. 2. Cortical and striatal expression patterns of βarr2 and GRK2 as well as
D2R PFC agonism. (A) Western blot analysis from WT mice probed with
antibodies to GRK2, βarr2, and βarr1 and GAPDH in cortex (CTX) compared
with STR and (B) quantification of Western blot band intensities normalized
to GAPDH (loading control; Ps < 0.05). IHC images of mouse brain sections
(cortical-striatal) stained with antibodies to (C) βarr2 and (D) GRK2. Loco-
motor responses to (E) bilateral local PFC injection 1 μg per side quinpirole
(QUIN), UNC9994A (94A), and aripiprazole (ARI) in WT mice followed by
systemic PCP injection (6 mg/kg i.p.; n = 8–11) or (F) bilateral local PFC in-
jection of 1 μg per side UNC9994A (94A) with or without cpd101 (0.5 μg per
side) inWTmice followed by systemic PCP injection (6 mg/kg i.p.; n = 8–10). *P <
0.05, compared with VEH + PCP; **P < 0.01, compared with VEH + PCP; #P <
0.05, compared with 94A + PCP.
Fig. 3. Distinct contribution of striatal and cortical D2Rs to the behavioral
effects of PCP. (A) D2f/f mice were injected with a control GFP virus (GFP-AAV)
or Cre-AAV in the PFC and 3 wk later, injected systemically with either saline
(SAL) or PCP (4 mg/kg i.p.); their locomotor response was recorded (n = 8–9).
**P < 0.01; ***P < 0.001 compare D2f/f pfcGFP-AAV with D2f/f pfcCre-AAV
(PCP) using a three-way RMANOVA [genotype × treatment × time interaction,
F(29, 720) = 1.947, P < 0.01] with post hoc Bonferroni tests. (B) D2f/f mice were
crossed with A2aCre mice (D2f/f A2aCre) to delete D2Rs in the STR and injected
systemically with either SAL or PCP (6 mg/kg i.p.); their locomotor response was
recorded (n = 8–13). **P < 0.01; ***P < 0.001 compare D2f/f with D2f/f A2aCre
(PCP) using a three-way RMANOVA [genotype × treatment × time interaction,
F(29, 840) = 3.722, P < 0.001] with post hoc Bonferroni tests.
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genotype differences between mice (Fig. 4 C–H). This higher dose
allowed us to achieve better separation of effects when treating with
APDs and biased compounds. Consistent with their antagonist
activity, all tested APDs and biased D2R ligands significantly
inhibited AMPH-induced locomotion in all control βarr2f/f mice
(Fig. 5, black bars) (Ps < 0.01). No genotype differences were
observed in mice lacking βarr2 in D1R+ neurons for all com-
pounds (Fig. 5 A and B) (Ps < 0.01). All three APDs and 75A
also inhibited the AMPH response (Ps < 0.01) in mice lacking
βarr2 in either all D2R+ (Fig. 5C) or striatal A2aR+ neurons
(Fig. 5E). However, in these mice, 94A showed markedly di-
minished antipsychotic-like activity compared with genotype
controls (Ps < 0.05), consistent with this compound being a se-
lective βarr2-biased D2R antagonist. Compared with other
APDs, the observations with 94A indicate that D2R-βarr2 an-
tagonism is sufficient but not necessary for efficacious antipsy-
chotic-like activity in the AMPH pharmacological model, which
is consistent with previous observations (60).
For PCP-induced responses, in mice lacking βarr2 in D1R+
neurons, all drugs significantly inhibited PCP-induced locomotion
compared with vehicle (VEH)-treated controls (Fig. 6A) (Ps <
0.05), and there were no genotype differences. ARI and 75A also
inhibited PCP-induced locomotion in mice lacking βarr2 in D2R+
striatal neurons (Fig. 6B) (Ps < 0.05) or all D2R+ neurons (Fig. 6C)
(Ps < 0.05) compared with genotype and VEH controls. In contrast
to the AMPH response (Fig. 4), however, we observed a loss of
94A activity only in mice lacking βarr2 in all D2R+ neurons
Fig. 4. Deletion of βarr2 in D2R-expressing neurons inhibits the AMPH re-
sponse. (A) βarr2f/f mice were crossed with both D1Cre and D2Cre mice to delete
βarr2 in all striatal neurons simultaneously to generate βarr2f/f D1D2Cre and
injected with 3 mg/kg AMPH; distance traveled was calculated for 120 min after
30 min of habituation compared with control βarr2f/f mice. Data were analyzed
using a two-way RMANOVA test [genotype × time interaction, F(29, 145) =
1.956, P < 0.01] followed by Bonferroni comparisons. (B) Total cumulative dis-
tance after injection of saline (SAL) and 3mg/kg AMPHwas calculated for βarr2f/f
D1D2Cre and βarr2f/f controls. **P < 0.01, using a two-way ANOVA (Bonferroni)
test (n = 7 mice for each genotype). (C) βarr2f/f D1Cre, (E) βarr2f/f D2Cre, or (G)
βarr2f/f A2aCre and their respective Cre-negative βarr2f/f controls were injected
with SAL or 2 mg/kg AMPH after 30 min of habituation, and locomotor activity
was measured for 120 min. Data were analyzed using a three-way RMANOVA
for D1βarr2 [genotype× time interaction, F(29, 116)= 0.4045, P= 0.9967; genotype ×
treatment interaction, F(1, 480) = 3.463, P = 0.0634], A2aβarr2 [genotype × time
interaction, F(87, 435) = 4.760; genotype × treatment interaction, F(1, 600) = 47.15,
P < 0.001], and D2βarr2 [genotype × time interaction, F(87, 261) = 3.324, P < 0.001;
genotype × treatment interaction, F(1, 360) = 66.37, P < 0.001] with post hoc
Bonferroni tests. (D, F, and H) Total cumulative (120 min) postinjection distance
after SAL or 2 or 3 mg/kg AMPH; n = 8 mice for each group. *P < 0.05, compared
with βarr2f/f using a two-way ANOVA (Bonferroni) test; **P < 0.01, compared with
βarr2f/f using a two-way ANOVA (Bonferroni) test. (I) ChAT-Cre mice were crossed
with βarr2f/f mice to generate βarr2f/f ChATCre or βarr2f/f controls, and total cu-
mulative distance after postinjection of SAL or 2 or 3 mg/kg AMPH was calculated;
n = 8 mice for each group.
Fig. 5. UNC9994A loses its antipsychotic-like activity in response to AMPH in
D2R+ and A2aR+ neuron-specific βarr2KO mice. Control mice (βarr2f/f) and (A)
βarr2f/f D1Cre, (C) βarr2f/f D2Cre, or (E) βarr2f/f A2aCre mice were injected with
vehicle (VEH); the antipsychotics haloperidol (HAL; 0.5 mg/kg), ARI (0.5 mg/kg),
or clozapine (CLOZ; 2 mg/kg); or βarr2-biased drugs UNC9994A (94A; 2 mg/kg)
or UNC9975A (75A; 0.5 mg/kg) followed by 3 mg/kg AMPH injection. Total
cumulative distance postinjection of AMPH for 120 min was calculated and
shows that all APDs and drugs, except UNC9994A, are able to inhibit the
AMPH response in the βarr2f/f D2Cre and βarr2f/f A2aCre mice. **P < 0.01,
compared with respective VEH control; $P < 0.001, compared with respective
VEH control; #P < 0.05 compare 94A between genotypes using a two-way
ANOVA (Bonferroni) test; ##P < 0.01 compare 94A between genotypes using a
two-way ANOVA (Bonferroni) test. Representative graphs of AMPH inhibition
by 94A for (B) βarr2f/f D1Cre, (D) βarr2f/f D2Cre, or (F) βarr2f/f A2aCre mice
compared with controls (βarr2f/f); n = 8 mice for each group. Data were ana-
lyzed by two-way RMANOVA [genotype × treatment interaction, F(1, 420) =
2.053, P = 0.1526, for βarr2f/f D1Cre; genotype × treatment interaction,
F(29, 420) = 3.858, P < 0.05, for βarr2f/f A2aCre; and genotype × treatment
interaction, F(29, 420) = 2.285, P < 0.01, for βarr2f/f D2Cre] with post hoc
Bonferroni tests.














(Fig. 6B) (P = 0.2526) but not in striatal D2R+ neurons (Fig. 6C)
(P < 0.05), suggesting a role for βarr2 outside the STR, because
A2aCre is essentially STR-selective. Although the D2Cre is
expressed in STR, PFC, and midbrain, a cortical role for βarr2 in
94A-mediated inhibition of PCP-induced locomotion is most likely,
because evidence suggests against a role for midbrain DA neuron
βarr2 (61) and the primary site of action for PCP is in the PFC.
However, to further rule out the contribution of midbrain pre-
synaptic βarr2 and confirm a role for cortical βarr2, we deleted
βarr2 in PFC and STR or PFC alone by injecting mCherry-Cre
AAV in the PFC of βarr2f/f A2aCre (PFC + STR βarr2KO) or
βarr2f/f mice (PFC βarr2KO) (Fig. S6); 94A inhibited PCP-induced
locomotion in PFC βarr2KO mice (Fig. 6D) (P < 0.05) but lost its
antipsychotic-like activity when βarr2 was deleted in both PFC and
STR (Fig. 6D), thus confirming a dual dependence on cortical and
striatal βarr2. These data suggest that cortical and striatal βarr2 are
necessary for the antipsychotic-like effect of 94A. Thus, our be-
havioral data further support our initial supposition that distinct
mechanisms might regulate the antipsychotic-like effect of D2R-
βarr2 signaling in the PFC (agonism) versus the STR (antagonism).
We next wanted to confirm the neuronal mechanism of these
distinct phenomena electrophysiogically in the PFC and STR.
Effect of 94A on Excitability of Cortical D2R+ Fast-Spiking Interneurons.
The PFC comprises multiple neuronal cell types, and many of
these neurons, in particular GABA interneurons and pyramidal
glutamatergic neurons, express D2Rs (56, 62–64). GABAergic
interneurons are thought to play a critical role in schizophrenia
pathophysiology in humans and animal models of schizophrenia.
Postmortem brain analyses of patients (65–71) and behavioral
studies in rodents have implicated GABAergic parvalbumin+
(PV+) fast-spiking interneurons (FSIs) in altered excitation–
inhibition imbalance and cognitive impairment in schizophrenia
(72, 73). The D2R agonist quinpirole increases FSI excitability in
adult rodents in a similar fashion as D1R agonists (64), suggesting
that this excitatory effect is not mediated by the canonical in-
hibitory Gαi/o activation but presumably, is through a G protein-
independent pathway. Our data suggest that the higher levels of
βarr2 and GRK2 in the cortex might support this G protein-
independent agonist signaling of D2R ligands (Figs. 1 and 2).
Additionally, the elevated βarr2 and GRK2 expression is present in
PFC PV+ FSI (Fig. S7) and presumably, pyramidal neurons (non-
PV+ cells) as well. Given the pharmacological, genetic, and be-
havioral evidence for the importance of FSIs in schizophrenia
pathophysiology, we chose to determine the functional impact of
higher cortical levels of βarr2 and GRK2 in FSIs. We performed
whole-cell, current clamp slice recordings in prefrontal GAD67+
FSI from control (βarr2+/+) and global βarr2KO mice and assessed
the effects of UNC9994A. FSIs were visually identified in acute
slices from Gad1-eGFP adult mice and further identified by their
responses to hyperpolarizing and depolarizing current injections
(Fig. 7A). As expected from previous studies with D2R agonists,
like quinpirole (64), ARI and 94A increased prefrontal FSI ex-
citability as measured by changes in FSI action potential frequency
in response to minimal amounts of depolarizing current injection.
The D2R partial agonist ARI (10 μM) elicited a modest increase
in action potential firing (+6.2 ± 1.4 Hz after 20 min of exposure
relative to a 10 min predrug baseline; n = 6) (Fig. 7B). This effect
was prevented by the D2R antagonist eticlopride (10 μM) and
even led to a slight decrease in FSI excitability (−2.1 ± 2.2 Hz after
20 min of exposure of 10 μM eticlopride and 10 μM ARI; n = 4)
(Fig. 7B). These data suggest that ARI has modest D2R agonist-
like activity on FSIs in the PFC and are consistent with the partial
agonist activity observed with ARI when GRK2 and βarr2 are
overexpressed in HEK293 cells (Fig. 1 B, D, and F). Interestingly,
94A (10 μM) elicited a significantly more robust increase in FSI
excitability compared with ARI (+25.8 ± 3.8 Hz after 20 min of
94A; +6.1 ± 1.4 Hz after 20 min of 10 μM ARI; n = 4 and n = 6,
respectively; P < 0.01) (Fig. 7 C and D). Bath application of eti-
clopride (10 μM) also prevented the increase in FSI excitability by
94A and again, led to a slight decrease in FSI excitability [−5.0 ±
12.6 Hz after 20 min of exposure to eticlopride and 94A (10 μM);
n = 3]. Additionally, the effects of 94A were dependent on βarr2-
signaling, because UNC9994A failed to enhance FSI excitability in
βarr2KO mice [+1.3 ± 1.6 Hz after 20 min of 94A (10 μM)] (Fig.
7E). Finally, the presence of the membrane-permeable GRK2
inhibitor cpd101 (30 μM) prevented the increase in FSI excitability
elicited by 94A (Fig. 7F) (−2.3 ± 3.2 Hz after 20 min of exposure of
cpd101 and 94A; n = 5). These data further highlight that 94A
requires GRK2 in addition to βarr2 to produce its D2R-dependent,
agonist-like effects in cortical FSI.
Effect of 94A on Excitability of Striatal D2R+ Medium Spiny Neurons.
Based on the above behavioral and biochemical observations,
because βarr2 and GRK2 levels are significantly lower in the STR
than in the PFC, one might expect that the agonist activity of 94A
would be reduced in striatal neurons. The D2R agonist quinpirole
decreased excitability of striatal medium spiny neurons [MSNs;
−6.8 ± 2.2 Hz after 20 min of quinpirole (10 μM); n = 8] (Fig. 8B,
black line). These findings are consistent with previous reports
showing that D2R agonists reduce the excitability of striatal MSNs
(74). Unlike quinpirole, 94A produced a negligible reduction in
striatal MSN excitability [−2.6 ± 1.0 Hz after 20 min of 94A
(10 μM); n = 8; P = 0.0137 compared with quinpirole] (Fig. 8 B
and C). Thus, 94A lacks agonist-like activity in striatal MSNs,
showing that D2R-βarr2–biased ligands can have distinct electro-
physiological actions in the PFC and STR.
Discussion
We used neuron-specific βarr2KO mice to characterize the role
of βarr2 in striatal and cortical circuits and their involvement in
Fig. 6. UNC9994A loses antipsychotic-like activity to PCP in D2R+ but not
A2aR+ neuron-specific βarr2KO mice. Control mice (βarr2f/f) and (A) βarr2f/f
D1Cre, (B) βarr2f/f D2Cre, or (C) βarr2f/f A2aCre mice were injected with VEH,
ARI (0.5 mg/kg), or βarr-biased drugs UNC9994A (94A; 2 mg/kg) and UNC9975A
(75A; 0.5 mg/kg) followed by 6 mg/kg PCP injection 10 min later. Total cumu-
lative distance postinjection of PCP for 120 min was calculated; n = 8–10 mice
for each group. Onemouse each from the βarr2f/f A2aCre 94A- and 75A-treated
groups was discarded based on criterion set in Statistical Analyses. *P < 0.05,
compared with respective VEH controls using a two-way ANOVA (Bonferroni)
test; $P < 0.001, compared with respective VEH controls using a two-way
ANOVA (Bonferroni) test. (D) mCherry-Cre AAV8 was injected into the PFC of
βarr2f/f A2aCre (PFC + STR βarr2KO) or βarr2f/f (PFC βarr2KO) mice followed by
injection 3 wk later with 94A (2 mg/kg i.p.) and PCP (6 mg/kg i.p.). Total cu-
mulative distance postinjection of PCP for 120 min was calculated; n = 8 mice
for each group. *P < 0.05, compared with respective VEH controls using a two-
way ANOVA (Bonferroni) test.
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pharmacological models of antipsychotic-like action. The βarr2-
biased D2R ligand 94A showed a paradoxical pharmacological
profile in biochemical, behavioral, and electrophysiological as-
says; 94A reversed the hyperlocomotor responses to both AMPH
and PCP through both striatal antagonism and cortical agonism.
Furthermore, the agonist activity of 94A increased the firing of
PFC D2R-expressing FSI in a βarr2- and GRK2-dependent man-
ner but did not mimic quinpirole’s ability to inhibit firing of striatal
D2R+ MSNs. These contrasting electrophysiological, behavioral,
and biochemical effects are consistent with higher PFC expression
of βarr2 and GRK2 compared with STR. These data suggest that
biased agonism of D2R-βarr2 in the PFC could add a dimension of
cortical benefits in addition to the striatal antagonist profile char-
acteristic of clinically efficacious APDs.
The opposite pharmacological action of 94A in the STR and
PFC in both behavioral and electrophysiological assays is con-
sistent with the higher expression of βarr2 and GRK2 in PFC
compared to STR. Although we show that both ARI and 94A
lack basal agonist activity when direct D2R-βarr2 interactions
are assessed by BRET in HEK293 cells, the partial agonist ac-
tivity of these compounds can be revealed when using assays such
as the TANGO and DiscoverX (33), which markedly amplify the
signal. Similarly, when the D2R-βarr2 BRET assay is performed
in the presence of overexpressed GRK2, which recapitulates
PFC expression patterns, both 94A and ARI now show similar
D2R-βarr2 partial agonist activity. However, somewhat unex-
pectedly, 94A is more efficacious than ARI not only at inhibiting
PCP-induced locomotion following local PFC injection but also, in
enhancing firing of PV+ FSIs of the PFC in a D2R-, GRK2-, and
βarr2-dependent manner. This enhanced PFC antipsychotic-like
effect and excitability of PV+ PFC FSIs by 94A can be attributed
to the relative balance between Gαi/o (neuronal inhibition) and
βarr2 (neuronal excitation) agonist activities; 94A has no Gαi/o
agonist activity (33), whereas ARI is a Gαi/o partial agonist. In
contrast to the PFC, the STR has low expression of GRK2 and
βarr2, and we showed in vitro that, with low levels of GRK2 ex-
pression, 94A is an antagonist at the D2R-βarr2 pathway. Fur-
thermore, 94A does not mimic the effect of the D2R agonist
quinpirole on striatal D2R+ MSN firing and inhibits the striatal
AMPH response consistent with its antagonist-like properties in
vivo. Therefore, although behaviorally, 94A has the same effect
(i.e., inhibition of the locomotor response), it has opposite effects
pharmacologically and on neuronal firing in the PFC versus STR.
Consistent with the above observations with 94A, D2R deletion
also has opposite effects in PFC versus STR on the PCP response.
Although the antipsychotic-like effect of 94A is selectively de-
pendent on the D2R-βarr2 pathway, other APDs do not require
βarr2 for their antipsychotic-like activity, suggesting that targeting
βarr2 is sufficient but not necessary for antipsychotic-like activity
(60). However, our data suggest that targeting the D2R-βarr2
pathway may generate unique antipsychotic-like actions that cur-
rent APDs do not achieve.
D2R antagonist and partial agonist APDs are the primary
treatment options for schizophrenia, but there are several disease
domains, such as negative symptoms and cognitive deficits, that are
unaffected by APDs. The prevalent DA hypothesis of schizophrenia
posits that this disorder presents with reduced cortical DA tone but
enhanced striatal DA release, with these spatially distinct mani-
festations being interdependent (20, 75–77). Brain imaging studies
Fig. 7. UNC9994A has βarr2- and GRK2-dependent, agonist-like effects in pre-
frontal GABAergic FSIs. (A) Sample recording from a prefrontal FSI showing re-
sponses to hyperpolarizing or depolarizing current injection. (B) ARI (10 μM)
increases action potential firing in prefrontal FSIs [+6.2 ± 1.4 Hz (relative to a
10-min predrug baseline) after 20 min of exposure; n = 6]. Bath application of
eticlopride (10 μM) prevented the increase in excitability elicited by ARI (−2.08 ±
2.2 Hz after 15 min of exposure of eticlopride + ARI; n = 4). **P < 0.01.
(C) UNC9994A (94A; 10 μM) elicited a greater increase in FSI excitability (+25.86 ±
3.8 Hz after 20 min of exposure; n = 4) compared with ARI. Data were analyzed
using a standard two-way ANOVA test. **P < 0.01. (D) Sample responses of FSIs
to depolarizing current pulses in various pharmacologic conditions showing an
increase in FSI excitability after bath application of 94A or ARI. (E) The 94A-
mediated increase in FSI excitability is absent in βarr2KO mice (+1.32 ±1.68 Hz
after 20 min of exposure; n = 4). (F) Bath application of the GRK2 inhibitor
cpd101 (30 μM) prevented the increase in excitability elicited by 94A (−2.3 ±
3.2 Hz after 20 min of exposure of cpd101 + 94A; n = 5). FS, fast spiking.
Fig. 8. UNC9994A lacks agonist-like effects in the STR. (A) Sample recording
from striatal MSNs showing responses to hyperpolarizing or depolarizing
current injection. (B) The D2R agonist quinpirole (10 μM) decreases action
potential firing in striatal MSNs (−6.8 ± 2.2 Hz relative to a 10-min predrug
baseline after 20 min of exposure; n = 8). UNC9994A (94A; 10 μM) elicits a
significantly smaller decrease in MSN excitability compared with quinpirole
(−2.6 ± 1.0 Hz after 20 min of exposure; n = 8). Data were analyzed using a
standard two-way ANOVA test. *P = 0.0137. (C) Representative traces of
striatal MSNs to depolarizing current pulses in control conditions and after
quinpirole or 94A application.














in schizophrenia patients have shown that AMPH-induced DA
release is enhanced in the STR (78) (hyperdopaminergia), whereas
a recent study has shown, for the first time, cortical hypo-
dopaminergia in schizophrenia patients (79). Partial agonists, such
as ARI, were originally developed to counteract these opposite
phenomena but have largely been unsuccessful in correcting
cortical dysfunction (80, 81). Our behavioral and electrophysio-
logical data show that the ARI-derived βarr2-biased D2R ligand,
94A, can act as a D2R-βarr2 agonist in the PFC but a D2R-βarr2
antagonist on striatal D2 MSNs, highlighting the feasibility of a
pharmacological approach, where a drug could potentially si-
multaneously counteract both the cortical hypodopaminergia
with D2R-βarr2 agonism and striatal hyperdopaminergia with
D2R-βarr2 antagonism in schizophrenia.
Our results indicate that 94A acts as an agonist at D2R-βarr2
signaling in GABAergic FSIs. This effect may contribute to the
antipsychotic-like action that we observed in PCP-induced loco-
motion and most likely, will contribute to resetting excitation in-
hibition balance in cortical circuits. However, we cannot exclude
the contribution of D2R-expressing pyramidal neurons that may
also have elevated levels of βarr2 and GRK2. However, DA re-
leased by PFC-projecting mesocortical DA neurons inhibits pyra-
midal neurons primarily by activating interneurons (82), suggesting
a temporally preceding role for FSIs. To target the exact subtype
of cortical neurons for more specific behavioral analyses would
require developing novel Cre driver lines involving at least triple-
intersectional approaches. Appropriate selectively targeted Cre
lines for various D2R neuronal subtypes in the PFC (83, 84) are
currently lacking. After appropriate targeting is achieved, signaling
effectors downstream of D2R-βarr2 in the PFC can be elucidated.
Although the downstream cellular targets of D2R-G protein, such
as PKA/DARPP32 signaling, are well-established (23, 25, 85),
possible downstream D2R-βarr2 signaling effectors, such as
GSK3β, AMPA, and NMDA receptors, are only now beginning
to be revealed (86, 87). In conclusion, our data provide evidence
suggesting that combining the concept of functional selectivity
and taking into account region- and cell-specific receptor and
transducer expression patterns have the potential to generate
more effective therapies and at the same time, reduce side effects.
Materials and Methods
Animals and Drugs. All mouse studies were conducted in accordance with the
NIH guidelines for animal care and use and through animal protocols ap-
proved by the Duke University Animal Care and Use Committee and Pfizer’s
Institutional Animal Care and Use Committee. All mice were housed in a
12-h light–dark cycle at a maximum of five per cage, provided with food and
water ad libitum, and tested at 10–20 wk of age. Details of mouse lines used,
generation of βarr2f/f animals, and drugs and chemicals used are in SI Ma-
terials and Methods.
Locomotor Activity. Activity was measured in an Accuscan Activity Monitor
(Accuscan Instruments) and performed as described (30, 88). Briefly, mice
were allowed to habituate to the open field for 30 min, injected with various
drugs, and returned to the open field. Locomotor activity was measured in
5-min intervals, and data were analyzed for the distance traveled in 5-min
increments over 120 min. All APDs and tool compounds were administered
i.p. and injected 10 min before AMPH or PCP injections.
IHC. Fifty-micrometer-thick vibratome cut sections of formalin-fixed mouse
brains were processed for IHC analyses as described previously (30). To assess
neuron-specific deletion of βarr2, antibodies to βarr2 (generated in rabbit; at
1:300; gift from Jeff Benovic, Thomas Jefferson University, Philadelphia), Cre
recombinase (mouse antibody MAB3120; at 1:500; EMD Millipore), and D2
neuron marker enkephalin (ENK; rabbit antibody; AB5026; at 1:500; EMD
Millipore) were used. Because both antibodies to βarr2 and ENK were from
rabbit, they were used in combination with antibodies to Cre only. Addition-
ally, because βarr2 levels in the STR are much lower, a TSA Amplification Sys-
tem (Perkin-Elmer) was used to enhance detection of βarr2. Antibodies to PV
(1:500; PVG-213; Swant Inc.) and GRK2/3 (1:500; 05–465; EMD Millipore) were
used to label PV+ interneurons and assess the levels of GRK2, respectively, in
these cells. All representative images are from IHC analyses from at least two to
three mice for each group.
Western Blot.Western blot analyses were performed on postmortem human or
drug-naïve mice brain tissue as described previously (30). For human brain
tissue, all procedures were carried out in compliance with an approved pro-
tocol from the University of Mississippi Medical Center Institutional Review
Board. Written informed consent was obtained from legally defined next of
kin for tissue collection and informant-based retrospective diagnostic inter-
views (Table S2). Human or mouse tissue lysates were loaded onto SDS gels
followed by transfer onto nitrocellulose membranes. Membrane blots were
incubated with primary antibody followed by IR secondary antibody (LICOR),
and the blots were developed using an LICOR Odyssey Detection System.
Details are in SI Materials and Methods.
Stereotaxic Surgeries and Virus. Deletion of βarr2 or D2Rs in the PFC was
achieved by a viral approach; βarr2f/f or D2f/f mice were stereotaxically injected
bilaterally with 0.5 μL AAV serotype 2/8 (UNC Viral Vector Core). βarr2f/f (PFC
βarr2KO) or A2aCre βarr2f/f (PFC + STR βarr2KO) mice were injected with
mCherry-Cre AAV, whereas D2f/f mice were injected with either GFP or
mCherry-Cre AAV at coordinates +2.5 mm anteroposterior (AP), ±0.3 mm
mediolateral (ML), and −1.8 mm dorsoventral (DV) from bregma to target the
prelimbic/infralimbic region of the PFC. Mice were allowed to recover for 3 wk
to allow for viral expression of GFP or mCherry-Cre before behavioral testing.
Cannulation and Local PFC Drug Injections. For local PFC injection of drugs, we
inserted bilateral guide cannulas (Plastics One) into the PFC of WT mice. The
bilateral guide cannulas were inserted at +2.0 mm AP with 1.0-mm spacing
(±0.5 mm ML) and −2.0 mm DV and fixed to the skull with dental cement.
Mice were allowed to recover for 2 wk, and then, drugs were injected using an
automated injection system. Drugs were dissolved in VEH [10% (vol/vol) DMSO
and 20% (vol/vol) hydroxypropyl cyclodextrin], and either 1 μg (Quinpirole and
UNC9994A) or 0.5 μg (cpd101–GRK2/3 inhibitor; Hello Bio, Bristol, UK) per
0.5 μL were injected per side at a rate of 0.4 μL/min. After local injection, mice
were placed in the activity monitors for 10 min before systemic (i.p.) injection
with PCP (6 mg/kg), and then, locomotor activity was recorded.
cAMP Inhibition Assay. To measure D2R Gαi-mediated cAMP inhibition, a split
luciferase-based cAMP biosensor (GloSensor; Promega) in HEK293T cells was
used. The assay was performed in a 384-well plate using a Wallac TriLux
Microbeta (Perkin-Elmer) Luminescence Counter. Details are in SI Materials
and Methods.
βarr BRET Assay. To measure D2R-mediated βarr2 recruitment, a mouse
D2Long receptor fused to C-terminal renilla luciferase and a Venus-tagged
N-terminal βarr2 (a gift from Jonathan Javitch, Columbia University, New
York) expressed in HEK293T cells were used in a BRET assay. The assay was
performed in a 96-well plate using a Mithras LB940 Multimode Plate Reader
(Berthold Technologies). Details are in SI Materials and Methods.
Electrophysiology.
Slice preparation. Three hundred-micrometer-thick coronal slices were cut from
7- to 10-wk-oldmice of either sex using a Leica VT1200SMicrotome. Gad1-EGFP
Tg (Jackson Immunoresearch Laboratories Inc.) and global βarr2−/− mice were
used in our electrophysiological studies. Acute slices were secured by placing a
harp along the midline between the two hemispheres.
Intracellular recording. Whole-cell patch recordings were obtained from visually
identified interneurons in layer V of infralimbic or prelimbic cortex or MSNs in
the STR using differential contrast video microscopy on an upright microscope
(BX51WI; Olympus). Recordings were obtained from FSI or MSNs of Gad1-eGFP
adult mice (n = 1 per animal), which were further identified by their responses
to hyperpolarizing and depolarizing current injections. Recordings were col-
lected using a Multiclamp 700A (Molecular Devices). Patch electrodes (tip re-
sistance = 4–6 MΩ) were filled with the following (in mM): 115 K-Gluconate,
10 HEPES, 20 KCl, 2 MgCl, 2 Mg-ATP, 2 Na-ATP, and 0.3 GTP. Slices were sub-
merged in artificial cerebrospinal fluid containing the following: 125 mM NaCl,
25 mM NaHCO3, 3.5 mM KCl, NaH2PO4, 2 mM CaCl2, 1 mMMgCl2, and 10 mM
glucose. All recordings were made at 32.5 °C ± 1 °C. Series resistance was
usually 15–20 MΩ, and experiments were discontinued if the series resistance
exceeded 30 MΩ.
Statistical Analyses. Data were analyzed by standard one- and two-way ANOVA
or two- and three-way repeated-measures ANOVA (RMANOVA) tests for
comparison between genotypes, treatments, or doses. Individual genotypes,
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treatments, or doses were compared using a post hoc Bonferroni’s test. Data
were analyzed for normality with equal variance, and only parametric tests
were used. Data points were excluded based on previously established
criterion and set to ±2 SDs from the group mean. Data are presented as
mean ± SEM.
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